Clinical Trials Logo

Supranuclear Palsy, Progressive clinical trials

View clinical trials related to Supranuclear Palsy, Progressive.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06209515 Active, not recruiting - Parkinson Disease Clinical Trials

Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study

DEGERWD
Start date: January 1, 2022
Phase:
Study type: Observational

In this retrospective register study, clinically classified individuals with neurodegenerative disease from the years 2010-2021 will be verified from the clinical records from KUH and Oulu University Hospital (OUH). Based on the Finnish social security number, these individuals will be linked to the the national registers of Statistics Finland and Finnish Social and Health Data Permit Authority Findata including incomes, sociodemographic factors, education, occupation, criminal records as well as to the national registers including the bought pharmaceuticals, comorbidities and causes of death. For each study case, 10 randomly selected control cases, matched with age, sex and geographical area, will be used. The aim of the study is to examine: - 1) The prevalence of criminal and other disruptive behaviour in groups of different neurodegenerative diseases prior to and after the diagnosis - 2) Changes in employment, residency,income, and marital status prior to and after the neurodegenerative disease diagnosis - 3) Hospital diagnoses and reimbursable drugs prior to and after the diagnosis - 4) Causes of death in patients with neurodegenerative disease to study excess mortality of the patients

NCT ID: NCT04993768 Active, not recruiting - Clinical trials for Progressive Supranuclear Palsy

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Start date: October 15, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.

NCT ID: NCT04734379 Active, not recruiting - Clinical trials for Progressive Supranuclear Palsy

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

ROCKIT-1
Start date: January 22, 2021
Phase: Phase 2
Study type: Interventional

A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients with the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome

NCT ID: NCT04658199 Active, not recruiting - Clinical trials for Progressive Supranuclear Palsy

A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

Start date: November 16, 2020
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with progressive supranuclear palsy (PSP).

NCT ID: NCT04539041 Active, not recruiting - Clinical trials for Progressive Supranuclear Palsy (PSP)

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

Start date: February 16, 2021
Phase: Phase 1
Study type: Interventional

This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.

NCT ID: NCT04008355 Active, not recruiting - Clinical trials for Progressive Supranuclear Palsy

A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP

Start date: June 22, 2020
Phase: Phase 2
Study type: Interventional

A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy. The patient study duration is 29 weeks including a washout period.

NCT ID: NCT02966145 Active, not recruiting - Clinical trials for Progressive Supranuclear Palsy (PSP)

4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

4RTNI-2
Start date: January 2016
Phase:
Study type: Observational

The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.

NCT ID: NCT01804452 Active, not recruiting - Clinical trials for Progressive Supranuclear Palsy

4 Repeat Tauopathy Neuroimaging Initiative

4RTNI
Start date: January 2014
Phase:
Study type: Observational

The purpose of this study is to evaluate several different tests, including brain imaging, eye movement testing, body fluid samples, measurements of memory and other thinking abilities, and measures of functional independence in the hope that this information can be used to guide diagnosis and treatment of PSP and CBD in the future. Recent advances in our understanding of the biological causes of these diseases offer hope for new treatments. As such treatments are developed, sensitive and specific biological measurements (biomarkers) will be needed to provide precise and direct measures of the state of the brain, which will improve the statistical power of clinical trials. Brain imaging with Magnetic Resonance Imaging (MRI) has previously been used to measure disease-related changes in the brain. The goal of this study is to identify the best methods of analysis (including eye movements, imaging, and behavioral measures) for tracking PSP and CBD over time. In addition, certain biomarkers in the blood and cerebrospinal fluid might also be useful for following these diseases over time. This study will examine the value of blood and CSF biomarkers relative to brain imaging and functional measures.

NCT ID: NCT01537549 Active, not recruiting - Clinical trials for Progressive Supranuclear Palsy

Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy

Start date: December 2011
Phase: Phase 1
Study type: Interventional

Studies have shown that alpha-lipoic acid and L-acetyl carnitine may have some neuroprotective activities and it is hoped that they could be helpful for people with neurodegenerative illnesses such as progressive supranuclear palsy (PSP). The purpose of this study is to find out whether the nutritional supplement alpha-lipoic acid/L-acetyl carnitine is safe and well-tolerated in individuals with PSP when given daily, and whether it affects their well-being, brain scan measurements and blood tests that measure the energy metabolism in cells.

NCT ID: NCT00653783 Active, not recruiting - Parkinson Disease Clinical Trials

Diagnostic and Prognostic Biomarkers in Parkinson Disease

PROBE
Start date: August 2007
Phase: N/A
Study type: Observational

The overall goal of PROBE is to evaluate the feasibility and potential utility of three markers (alpha-synuclein, transcriptomic profiles and olfactory function) to determine the risk or prognosis of PD.